Cargando…

A randomized pilot trial evaluating safety and immunogenicity of recMAGE-A3 + AS15 immunotherapeutic administered by intramuscular versus intradermal/subcutaneous routes

Detalles Bibliográficos
Autores principales:	Slingluff, Craig L, Petroni, Gina R, Olson, Walter C, Chianese-bullock, Kimberly A, Smith, Kelly T, Smolkin, Mark E, Galeassi, Nadedja, Grosh, William, Weiss, Geoffrey, Scott, Kristy, Hornillo, Ana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4288705/ http://dx.doi.org/10.1186/2051-1426-2-S3-P60

Ejemplares similares

Immunogenicity in humans of a transdermal multipeptide melanoma vaccine administered with or without a TLR7 agonist
por: Meneveau, Max O, et al.
Publicado: (2021)

A multi-epitope melanoma helper peptide vaccine durably increases Th1 cytokine production by responding lymphocytes
por: Dillon, Patrick M, et al.
Publicado: (2013)

A melanoma helper peptide vaccine increases Th1 cytokine production by leukocytes in peripheral blood and immunized lymph nodes
por: Dillon, Patrick M, et al.
Publicado: (2014)

A multipeptide vaccine plus toll-like receptor agonists LPS or polyICLC in combination with incomplete Freund’s adjuvant in melanoma patients
por: Melssen, Marit M., et al.
Publicado: (2019)

Trial to evaluate the immunogenicity and safety of a melanoma helper peptide vaccine plus incomplete Freund’s adjuvant, cyclophosphamide, and polyICLC (Mel63)
por: Slingluff, Jr., Craig L, et al.
Publicado: (2021)

Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal delivery()
por: Meyer, Joel, et al.
Publicado: (2013)

Phase I/II clinical trial of a helper peptide vaccine plus PD-1 blockade in PD-1 antibody-naïve and PD-1 antibody-experienced patients with melanoma (MEL64)
por: Vavolizza, Rick D, et al.
Publicado: (2022)

P25. Access to diagnostics: a bottleneck for immunotherapeutics development - case example of MAGE-A3 cancer immunotherapeutic
por: Lykopoulos, K, et al.
Publicado: (2014)

Immunogenicity and Reactogenicity of Messenger RNA Coronavirus Disease 2019 Vaccine Booster Administered by Intradermal or Intramuscular Route in Thai Older Adults
por: Assantachai, Prasert, et al.
Publicado: (2023)

A pilot study of the immunogenicity of a 9-peptide breast cancer vaccine plus poly-ICLC in early stage breast cancer
por: Dillon, Patrick M., et al.
Publicado: (2017)

Shipping blood to a central laboratory in multicenter clinical trials: effect of ambient temperature on specimen temperature, and effects of temperature on mononuclear cell yield, viability and immunologic function
por: Olson, Walter C, et al.
Publicado: (2011)

Phase I/II trial of a long peptide vaccine (LPV7) plus toll-like receptor (TLR) agonists with or without incomplete Freund’s adjuvant (IFA) for resected high-risk melanoma
por: Patel, Sapna P, et al.
Publicado: (2021)

Pilot clinical trials testing the safety and effects on the metastatic melanoma microenvironment of intratumoral interferon-gamma or imiquimod, plus a multipeptide melanoma vaccine
por: Mauldin, Ileana S, et al.
Publicado: (2015)

Immunologic hierarchy and promiscuity of melanoma helper peptides
por: Hu, Yinin, et al.
Publicado: (2013)

Models and methods to characterise levonorgestrel release from intradermally administered contraceptives
por: Al Dalaty, Adnan, et al.
Publicado: (2021)

A Meta‐analysis of intradermal versus intramuscular influenza vaccines: Immunogenicity and Adverse Events
por: Marra, Fawziah, et al.
Publicado: (2012)

Sedative effects of intramuscular alfaxalone administered to cats
por: TAMURA, Jun, et al.
Publicado: (2015)

Cellular immune response following pre-exposure and postexposure rabies vaccination by intradermal and intramuscular routes
por: Venkataswamy, Manjunatha Muniswamappa, et al.
Publicado: (2015)

Fractional dose of intradermal compared to intramuscular and subcutaneous vaccination - A systematic review and meta-analysis
por: Schnyder, Jenny L., et al.
Publicado: (2020)

Tumor Mouse Model Confirms MAGE-A3 Cancer Immunotherapeutic As an Efficient Inducer of Long-Lasting Anti-Tumoral Responses
por: Gérard, Catherine, et al.
Publicado: (2014)

Association of homogeneous inflamed gene signature with a better outcome in patients with metastatic melanoma treated with MAGE-A3 immunotherapeutic
por: Baurain, Jean-François, et al.
Publicado: (2018)

Current evidence on intradermal influenza vaccines administered by Soluvia™ licensed micro injection system
por: Icardi, Giancarlo, et al.
Publicado: (2012)

Seroconverting nonresponder of high-dose intramuscular HBV vaccine with intradermal HBV vaccine: A case report
por: Das, Manjusha, et al.
Publicado: (2017)

Comparison of antibody titres between intradermal and intramuscular rabies vaccination using inactivated vaccine in cattle in Bhutan
por: Wangmo, Karma, et al.
Publicado: (2019)

Intradermal versus intramuscular COVID-19 vaccination aiming at protection for delta variant: cost utility analysis
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2022)

Safety and immunogenicity of investigational seasonal influenza hemagglutinin DNA vaccine followed by trivalent inactivated vaccine administered intradermally or intramuscularly in healthy adults: An open-label randomized phase 1 clinical trial
por: Carter, Cristina, et al.
Publicado: (2019)

Dynamic changes in cellular infiltrates with repeated cutaneous vaccination: a histologic and immunophenotypic analysis
por: Schaefer , Jochen T, et al.
Publicado: (2010)

Safety and immunogenicity of MAGE-A3 cancer immunotherapeutic with dacarbazine in patients with MAGE-A3-positive metastatic cutaneous melanoma: an open phase I/II study with a first assessment of a predictive gene signature
por: Grob, Jean-Jacques, et al.
Publicado: (2017)

Pathogenicity of the MAGE family
por: Li, Sanyan, et al.
Publicado: (2021)

Optimising CN54gp140 plasmid delivery by comparing intramuscular and intradermal vaccination combinations with and without electroporation
por: Mann, JF, et al.
Publicado: (2012)

Long-term immunogenicity of the influenza vaccine at reduced intradermal and full intramuscular doses among healthy young adults
por: Song, Joon Young, et al.
Publicado: (2013)

Immunogenicity and Safety of Reduced-Dose Intradermal vs Intramuscular Influenza Vaccines: A Systematic Review and Meta-analysis
por: Egunsola, Oluwaseun, et al.
Publicado: (2021)

Successful response of intradermal hepatitis B vaccine in nonresponders of intramuscular hepatitis B vaccine in general and hemodialysis population
por: Hanif, Farina M., et al.
Publicado: (2020)

Intradermal needle-free injection prevents African Swine Fever transmission, while intramuscular needle injection does not
por: Salman, Muhammad, et al.
Publicado: (2023)

Comparative Evaluation of Intradermal vis-à-vis Intramuscular Pre-Exposure Prophylactic Vaccination against Rabies in Cattle
por: Gopalaiah, Swathi, et al.
Publicado: (2023)

Prospective assessment of a gene signature potentially predictive of clinical benefit in metastatic melanoma patients following MAGE-A3 immunotherapeutic (PREDICT)
por: Saiag, P., et al.
Publicado: (2016)

Reversion of Ebolavirus Disease from a Single Intramuscular Injection of a Pan-Ebolavirus Immunotherapeutic
por: Kuang, Erin, et al.
Publicado: (2022)

In vivo enhancement of the MAGE-specific cellular immune response by a recombinant MAGE1-MAGE3-TBHSP70 tumor vaccine
por: Junwei, Wang, et al.
Publicado: (2016)

Erratum to: In vivo enhancement of the MAGE-specific cellular immune response by a recombinant MAGE1-MAGE3-TBHSP70 tumor vaccine
por: Junwei, Wang, et al.
Publicado: (2017)

Comparing immune response of intradermal low dose versus intramuscular high dose of hepatitis B vaccination in hemodialysis patients
por: Momeni, Ali, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_7741uj7kitg0aisgbes6vf07mr